SequelSEC

Traws Pharma, Inc. TRAW

Pharmaceutical Preparations · CIK 0001130598 · Fiscal year ends 1231

Revenue
$2.79M
Fiscal year ended 2025-12-31
Operating income
-$17.88M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$9.80MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.65Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income1.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue3.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin328.7%99th
Revenue YoY growth1134.5%96th
Current ratio0.72x12th
Operating margin-640.7%38th
SBC / revenue26.1%52th

Traws Pharma, Inc. (TRAW) reported revenue of $2.79M and net income of $9.17M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Traws Pharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Traws Pharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$2.79M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$17.88M
Net income$9.17M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$8.52M
Selling & marketingUnavailable

Balance

Traws Pharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalentsUnavailable
Total assets$10.62M
Current assets$7.98M
Total liabilities$11.25M
Current liabilities$11.15M
Total equity incl. NCI-$629.00K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$3.79M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$5.65M

Cash flow

Traws Pharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$18.18M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$3.20M
Net change in cash-$17.52M
Stock-based compensation$728.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$61.00K

Derived

Traws Pharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-640.7%
FCF marginUnavailable
SBC / revenue26.1%
Current ratio0.72x
Revenue YoY growth1134.5%
Net margin328.7%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TRAW in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.